141 results on '"Ke, E."'
Search Results
2. First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
3. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
4. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets
5. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
6. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): a phase 2, randomized, controlled trial
7. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
8. Genomic and immune characteristics ofHER2‐mutated non‐small cell lung cancer and response to immune checkpoint inhibitor‐based therapy
9. HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia‐Pacific region: a longitudinal cohort study
10. 余弦编码复用多光谱关联成像技术研究
11. A Unique Population of Lipid-Associated Macrophages in Cerebrospinal Fluid: Implications for NSCLC Leptomeningeal Metastases Development and Osimertinib Resistance
12. Second-order complex linear differential equations with special functions or extremal functions as coefficients
13. Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy.
14. Efficacy of immune checkpoint inhibitors in patients with non–small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.
15. P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs
16. Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers
17. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study
18. Study on spectral encoded computational ghost imaging
19. Genomic Stability and Non-Exhausted Immune Phenotype in Indolent T4N0M0 (Diameter ≥7 cm) Non-Small Cell Lung Cancers
20. Clinical effects of probiotics in ordinary-type COVID-19 patients with diarrhea
21. 593P MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC).
22. P3.01-64 Preliminary Data of Diverse Therapies in Patients with Advanced Non–Small-Cell Lung Cancer Harbouring RET-Rearrangement
23. EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
24. Measurement of Extinction Coefficient of Near-surface Aerosol by CCD Lidar in the Daytime
25. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
26. Preparation and characterization of Si modified Ge-9 cluster
27. Finite-Time Chaos Control and Synchronization of the New Chaotic System with Unknown Parameters
28. Observations of Atmospheric CO2 Concentration Profiles over Hefei Area with Raman Lidar
29. The first identified case of pandemic H1N1 influenza in pigs in Australia
30. Measurement of Extinction Coefficient of Near-surface Aerosol by CCD Lidar in the Daytime
31. P3.02b-095 Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs
32. 439O Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs
33. 552P Genome characteristics of stage I lung adenocarcinoma associated with distinct progression patterns
34. High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies
35. [Measurement of path transverse wind velocity profile using light forward scattering scintillation correlation method]
36. EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
37. Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
38. Distribution and prognosis of uncommon metastases from non-small cell lung cancer
39. 468P Clinical characteristics of T790M in pre and post treatment with EGFR TKIs
40. Nonlinearity in social dynamics – order versus chaos
41. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting
42. A comparative study assessing a new tool for occluding parenchymal blood flow during liver resection for hepatocellular carcinoma
43. Does Dietary Protein Reduce Hip Fracture Risk in Elders? The Framingham Osteoporosis Study
44. Emerging paradigms in targeted treatments for Asian patients with NSCLC
45. Research on Possible Effects of Atmospheric Optical Characteristics on Laser Propagation in Arid Area
46. Analysis on Molecular Number Density Distribution in the Middle Atmosphere with 16 Years′ Lidar Data in Hefei
47. シツ ト リョウ ニ カンスル ジュヨウ リロン
48. Research on Possible Effects of Atmospheric Optical Characteristics on Laser Propagation in Arid Area
49. Analysis on Molecular Number Density Distribution in the Middle Atmosphere with 16 Years′ Lidar Data in Hefei
50. 123I-interleukin-2: Biochemical characterization and in vivo use for imaging autoimmune diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.